Cidara Therapeutics
CDTX
CDTX was delisted on the 6th of January, 2026.
46 hedge funds and large institutions have $83.7M invested in Cidara Therapeutics in 2015 Q2 according to their latest regulatory filings, with 46 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$31.1M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$17.6M |
| 3 |
Goldman Sachs
New York
|
+$5.03M |
| 4 |
PA
Perceptive Advisors
New York
|
+$4.61M |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$4.54M |
Top Sellers
CDTX Hedge Fund Activity: Q2 2015 in Review
46 of the 3,729 institutional investors tracked by Wall St. Rank reported a position in Cidara Therapeutics (CDTX) for Q2 2015, worth a combined $83.7M.
Buyers outnumbered sellers: 46 funds opened new CDTX positions and 0 closed out — a net gain of 46 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Fidelity Investments, opening a new position worth an estimated $31.1M.
- 46 institutional investors held Cidara Therapeutics (CDTX) as of Q2 2015, up from 0 in Q1 2015.
- Funds reported $83.7M of Cidara Therapeutics stock for Q2 2015.
- 46 funds opened new Cidara Therapeutics positions in Q2 2015 and 0 closed out, a net change of +46 holders.
- The largest Cidara Therapeutics buyer in Q2 2015 was Fidelity Investments, an estimated $31.1M added.
Based on aggregated 13F filings for Q2 2015.